Abstract: A process for centralized user file encapsulation, encryption, notarization and verification using a blockchain and a system that certifies data in a proprietary “capsule” file format, with tamper-proof blockchain are disclosed. By utilizing a hybridization of both cloud and blockchain storage mechanisms, the present invention allows for the performant and cost-effective certification of large amounts of data. Furthermore, the generation of the capsule allows for users to store both the data payload and its digital notarization. The system then allows for users to share the capsule with others (by way of permissions enforced by the notary system) and upload it for verification of authenticity at a later point in time.

Abstract: Pharmaceutical compositions especially for internal application which create lyotropic liquid crystals when in contact with aqueous phase. The pharmaceutical compositions consist of: A hydrophobic active ingredient with immunomodulatory effect from a group of N-methylated cyclic undecapeptides or macrolide antibiotics, in quantity 1-35 weight % in a carrier medium containing B at least one absorption promoter allowing for contact of the drug with a biological membrane or passing of the drug through in quantity 1-40 weight %, C nonlipidic vehicle containing at lest one of the below mentioned substances: C1 surfactant or mixed surfactant with HLB>9, in quantity 1-80 weight % C2 lipophilic solvent from group of higher fatty alcohols in quantity 1-30 weight % C3 at least one cosurfactant in quantity 1-50 weight %, while a ratio among the individual components of the product is A:B:C=1:0.5-4:5-8.

Abstract: Provided are therapeutic compositions which provide high bioavailability of the active ingredients from the group of cyclosporin, at the same time permitting concentrations in dosage forms higher than 10%.

Abstract: Provided are therapeutic compositions which provide high bioavailability of the active ingredients from the group of cyclosporin, at the same time permitting concentrations in dosage forms higher than 10%.

Abstract: Therapeutical compositions comprising from 0.1 to 20% by weight of a cyclosporin and a vehicle comprising from 1 to 60% by weight of polyethers constituted by, preferably, substances like ethoxy diglycol or polyethylene glycols 300 to 600 and/or substances like preferably dimethyl isosorbide, dimethyl isoidide and dimethyl isomannide, and from 1 to 60% by weight of a mixture of glyceryl monoesters of C.sub.8 -C.sub.22 fatty acids and hexaglyceryl to pentadecaglyceryl monoesters of C.sub.8 -C.sub.22 fatty acids in a ratio of 1:2 to 1:6. The therapeutical compositions preferably additionally comprise further adjuvants like anti-oxidants, preserving agents and stabilizers, flavoring agents, thickening agents and diluents. The compositions for external use preferably additionally comprise lipoaminoacids.

Abstract: Medical preparations (drugs) containing N-methylated cyclic undecapeptides, especially for internal use, characterized by the presence of 0.1 to 20 weight parts of compounds from the group of cyclosporins (A), 0.3 to 60 weight parts of emulsifier (B) containing anhydromanitol oleylether and/or lactoglyceride and/or citrogylceride, 0.1 to 10 weight parts of emulsion stabilizer (C) containing aluminium-magnesium hydroxy-stearate as a lipogel and 0.2 to 40 weight parts of a solvent (D) composed of 1,4: 3,6-dianhydro-2,5-di-O-methyl-D-glucitole and/or 1,3-dimethyl-2-imidazolidone and/or ethanol, with the ratio A:B being equal to 1:05-1:30.

Abstract: Process for the preparation of 3,14.beta.-dihydroxy-17-normorphinan ##STR1## A suitable economic process for the preparation of 3,14.beta.-dihydroxy-17-normorphinan of a general formula (I) is being solved, which is a key intermediate of a semisynthetic synthesis of an effective analgesic of Butorphanol from thebaine.Synthesis includes a two step N-demethylation, and concerted dephenoxylation of 4-phenoxy-14.beta.-hydroxy-3-methoxymorphinan in the first step by means of a chloroformate, then, in the second step, by means of sodium action in a liquid ammonia, and by means of the following O-demethylation under action of a complex of aluminium chloride - dialkylsulfide.